Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prostate Cancer, Castration Resistant”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01867333
What this trial is testing

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 57
Not applicableStudy completedNCT02380274
What this trial is testing

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

Who this might be right for
Prostate CancerCastration-resistant Prostate CancerMetastatic Prostate Cancer
Astellas Pharma Global Development, Inc. 1,030
Testing effectiveness (Phase 2)Looking for participantsNCT07332455
What this trial is testing

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

Who this might be right for
Neoplasms, Prostate
GlaxoSmithKline 54
Not applicableStudy completedNCT05520138
What this trial is testing

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Pfizer 5,506
Testing effectiveness (Phase 2)Study completedNCT01106352
What this trial is testing

Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

Who this might be right for
Bone MetastasesCastration-Resistant Prostate Cancer
Bayer 70
Not applicableEnded earlyNCT02370355
What this trial is testing

Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Prostate Carcinoma
University of Southern California 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT06029998
What this trial is testing

Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
University of Utah 22
Testing effectiveness (Phase 2)UnknownNCT05955209
What this trial is testing

Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Peking University Cancer Hospital & Institute 40
Early research (Phase 1)Ended earlyNCT04077021
What this trial is testing

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Adenocarcinoma
Calibr, a division of Scripps Research 22
Testing effectiveness (Phase 2)Looking for participantsNCT07562438
What this trial is testing

Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
First Affiliated Hospital of Fujian Medical University 20
Testing effectiveness (Phase 2)WithdrawnNCT02420587
What this trial is testing

AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center
Not applicableStudy completedNCT05968599
What this trial is testing

Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Pfizer 2,731
Testing effectiveness (Phase 2)Looking for participantsNCT07730021
What this trial is testing

ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors
Astellas Pharma Global Development, Inc. 392
Early research (Phase 1)UnknownNCT05902247
What this trial is testing

Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Erasmus Medical Center 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07104643
What this trial is testing

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）

Who this might be right for
mCRPC
TYK Medicines, Inc 48
Not applicableStudy completedNCT00428220
What this trial is testing

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Who this might be right for
Metastatic Breast CancerAdvanced Breast CancerMetastatic Castration Resistant Prostate Cancer+9 more
Pfizer 223
Testing effectiveness (Phase 2)Study completedNCT03878823
What this trial is testing

Safety and Pharmacokinetics of ODM-209

Who this might be right for
Prostate Cancer MetastaticAdvanced Breast CancerCastration-resistant Prostate Cancer+1 more
Orion Corporation, Orion Pharma 38
Early research (Phase 1)Study completedNCT01884285
What this trial is testing

AZD8186 First Time In Patient Ascending Dose Study

Who this might be right for
Advanced Castrate-resistant Prostate Cancer CRPCSquamous Non-Small Cell Lung Cancer sqNSCLCTriple Negative Breast Cancer TNBC
AstraZeneca 147
Testing effectiveness (Phase 2)Active Not RecruitingNCT05682443
What this trial is testing

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
OncoC4, Inc. 148
Post-approval studies (Phase 4)Active Not RecruitingNCT04597125
What this trial is testing

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Bayer 654
Next Page